文献速递骨软组织肉瘤与黑色素瘤

骨肉瘤的生存与预后:EURAMOS-1(欧洲与美国骨肉瘤研究)队列2000余例患者结局

Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort.
PubMed 文献 · Eur J Cancer · 2019-01-25

EURAMOS-1注册了2260例≤40岁的高级别骨肉瘤患者,接受甲氨蝶呤、多柔比星和顺铂三药标准方案。中位随访54个月,3年和5年无事件生存率分别为59%和54%,总生存率分别为79%和71%。肺转移、非肺转移和轴向骨肿瘤部位为不良预后因素,毛细血管扩张型和组织学 unspecified 传统型预后较好。

要点

  • 中位随访54个月,全队列3年无事件生存率59%,5年54%。
  • 诊断时肺转移(HR=2.34)、非肺转移(HR=1.94)和轴向骨肿瘤(HR=1.53)为最不利因素。
  • 局部病变术后完全缓解者,组织学反应差与术后结局差相关(HR=2.13)。

核心结论

  • EURAMOS-1注册的2000余例患者数据显示生存率与机构或协作组级骨肉瘤试验一致,需进一步努力改善可识别的高危患者结局。

研究设计与样本

  • EURAMOS-1为四个研究组协作的随机对照试验,纳入≤40岁、M0或M1期骨骼高级别骨肉瘤且所有部位完全手术切除被认为可能的患者。
  • 以甲氨蝶呤、多柔比星和顺铂三药联合定义为标准化疗。
  • 2005年4月至2011年6月共注册2260例患者,报告全队列的生存结局和预后因素。

主要发现

  • 全注册患者自活检起中位随访54个月(四分位距38-73),3年和5年无事件生存率分别为59%(95%CI 57-61%)和54%(95%CI 52-56%)。
  • 多因素分析显示诊断时最不利因素为肺转移(HR=2.34,95%CI 1.95-2.81)、非肺转移(HR=1.94,95%CI 1.38-2.73)或轴向骨肿瘤部位(HR=1.53,95%CI 1.10-2.13)。
  • 与软骨母细胞型相比,毛细血管扩张型(HR=0.52,95%CI 0.33-0.80)和未指定传统型(HR=0.67,95%CI 0.52-0.88)组织学亚型与较好预后相关。
  • 自活检起3年和5年总生存率分别为79%(95%CI 77-81%)和71%(95%CI 68-73%)。
  • 就诊时局部病变且术后完全缓解的患者中,组织学反应差与术后更差结局相关(HR=2.13,95%CI 1.76-2.58)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: High-grade osteosarcoma is a primary malignant bone tumour mainly affecting children and young adults. The European and American Osteosarcoma Study (EURAMOS)-1 is a collaboration of four study groups aiming to improve outcomes of this rare disease by facilitating randomised controlled trials. METHODS: Patients eligible for EURAMOS-1 were aged ≤40 years with M0 or M1 skeletal high-grade osteosarcoma in which case complete surgical resection at all sites was deemed to be possible. A three-drug combination with methotrexate, doxorubicin and cisplatin was defined as standard chemotherapy, and between April 2005 and June 2011, 2260 patients were registered. We report survival outcomes and prognostic factors in the full cohort of registered patients. RESULTS: For all registered patients at a median follow-up of 54 months (interquartile range: 38-73) from biopsy, 3-year and 5-year event-free survival were 59% (95% confidence interval [CI]: 57-61%) and 54% (95% CI: 52-56%), respectively. Multivariate analyses showed that the most adverse factors at diagnosis were pulmonary metastases (hazard ratio [HR] = 2.34, 95% CI: 1.95-2.81), non-pulmonary metastases (HR = 1.94, 95% CI: 1.38-2.73) or an axial skeleton tumour site (HR = 1.53, 95% CI: 1.10-2.13). The histological subtypes telangiectatic (HR = 0.52, 95% CI: 0.33-0.80) and unspecified conventional (HR = 0.67, 95% CI: 0.52-0.88) were associated with a favourable prognosis compared with chondroblastic subtype. The 3-year and 5-year overall survival from biopsy were 79% (95% CI: 77-81%) and 71% (95% CI: 68-73%), respectively. For patients with localised disease at presentation and in complete remission after surgery, having a poor histological response was associated with worse outcome after surgery (HR = 2.13, 95% CI: 1.76-2.58). In radically operated patients, there was no good evidence that axial tumour site was associated with worse outcome. CONCLUSIONS: In conclusion, data from >2000 patients registered to EURAMOS-1 demonstrated survival rates in concordance with institution- or group-level osteosarcoma trials. Further efforts are required to drive improvements for patients who can be identified to be at higher risk of adverse outcome. This trial reaffirms known prognostic factors, and owing to the large numbers of patients registered, it sheds light on some additional factors to consider.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Smeland S, Bielack SS, Whelan J, et al. Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort. Eur J Cancer. 2019. PMID: 30685685. doi:10.1016/j.ejca.2018.11.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。